Delphia Therapeutics
Yun Feng is a seasoned scientist with extensive experience in cell biology and assay development. Currently serving as a Principal Scientist at Delphia Therapeutics since May 2023, Yun previously held the position of Associate Principal Scientist at KSQ Therapeutics, Inc., where leadership in cell-based assay development for Immuno-oncology targets was a primary focus. Prior roles at Novartis Institutes for BioMedical Research included progression through various titles, culminating as Principal Scientist I, while earlier experience involved research technician duties at the MIT Center for Cancer Research and a scientist role at Genome Therapeutics Corporation. Yun holds an M.S. in Molecular Genetics from Syracuse University and a B.S. in Biochemistry from Nankai University.
This person is not in any teams
Delphia Therapeutics
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.